214 related articles for article (PubMed ID: 29590326)
41. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
[TBL] [Abstract][Full Text] [Related]
42. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
[TBL] [Abstract][Full Text] [Related]
43. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J; Ewer KJ; Ogbe A; Pace M; Adele S; Adland E; Alagaratnam J; Aley PK; Ali M; Ansari MA; Bara A; Bittaye M; Broadhead S; Brown A; Brown H; Cappuccini F; Cooney E; Dejnirattisai W; Dold C; Fairhead C; Fok H; Folegatti PM; Fowler J; Gibbs C; Goodman AL; Jenkin D; Jones M; Makinson R; Marchevsky NG; Mujadidi YF; Nguyen H; Parolini L; Petersen C; Plested E; Pollock KM; Ramasamy MN; Rhead S; Robinson H; Robinson N; Rongkard P; Ryan F; Serrano S; Tipoe T; Voysey M; Waters A; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Screaton GR; Winston A; Hill AVS; Gilbert SC; Pollard AJ; Fidler S; Fox J; Lambe T;
Lancet HIV; 2021 Aug; 8(8):e474-e485. PubMed ID: 34153264
[TBL] [Abstract][Full Text] [Related]
45. Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis.
Koh JH; Lee J; Kim SH; Kwok SK; Ju JH; Park SH
J Rheumatol; 2018 Apr; 45(4):465-469. PubMed ID: 29419465
[TBL] [Abstract][Full Text] [Related]
46. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
Levin MJ; Oxman MN; Zhang JH; Johnson GR; Stanley H; Hayward AR; Caulfield MJ; Irwin MR; Smith JG; Clair J; Chan IS; Williams H; Harbecke R; Marchese R; Straus SE; Gershon A; Weinberg A;
J Infect Dis; 2008 Mar; 197(6):825-35. PubMed ID: 18419349
[TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
[TBL] [Abstract][Full Text] [Related]
48. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
[TBL] [Abstract][Full Text] [Related]
49. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
[TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.
Parrino J; McNeil SA; Lawrence SJ; Kimby E; Pagnoni MF; Stek JE; Zhao Y; Chan IS; Kaplan SS
Vaccine; 2017 Mar; 35(14):1764-1769. PubMed ID: 28268074
[TBL] [Abstract][Full Text] [Related]
51. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
[TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
Rosenberg ES; Graham BS; Chan ES; Bosch RJ; Stocker V; Maenza J; Markowitz M; Little S; Sax PE; Collier AC; Nabel G; Saindon S; Flynn T; Kuritzkes D; Barouch DH;
PLoS One; 2010 May; 5(5):e10555. PubMed ID: 20479938
[TBL] [Abstract][Full Text] [Related]
53. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
Weinberg A; Canniff J; Rouphael N; Mehta A; Mulligan M; Whitaker JA; Levin MJ
J Immunol; 2017 Jul; 199(2):604-612. PubMed ID: 28607114
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
[TBL] [Abstract][Full Text] [Related]
55. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
Reither K; Katsoulis L; Beattie T; Gardiner N; Lenz N; Said K; Mfinanga E; Pohl C; Fielding KL; Jeffery H; Kagina BM; Hughes EJ; Scriba TJ; Hanekom WA; Hoff ST; Bang P; Kromann I; Daubenberger C; Andersen P; Churchyard GJ
PLoS One; 2014; 9(12):e114602. PubMed ID: 25490675
[TBL] [Abstract][Full Text] [Related]
57. Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy.
Tovar Salazar A; McKhann A; Chen H; Bosch RJ; Weinberg A
AIDS Res Hum Retroviruses; 2019 Oct; 35(10):890-895. PubMed ID: 31179712
[TBL] [Abstract][Full Text] [Related]
58. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
59. Live attenuated herpes zoster vaccine for HIV-infected adults.
Shafran SD
HIV Med; 2016 Apr; 17(4):305-10. PubMed ID: 26315285
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
